Pamela L. Zeitlin spends much of her time researching Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Internal medicine, Molecular biology and Genetic enhancement. Her Cystic fibrosis research is multidisciplinary, incorporating perspectives in Phenylbutyrate, Immunology, Pathology, Chloride channel and Bronchoalveolar lavage. Her studies deal with areas such as Secretion and Protein kinase A as well as Cystic fibrosis transmembrane conductance regulator.
Pamela L. Zeitlin combines subjects such as Gastroenterology, Placebo and Endocrinology with her study of Internal medicine. The various areas that she examines in her Molecular biology study include Cell culture and Endoplasmic reticulum. Her research in Genetic enhancement focuses on subjects like Adeno-associated virus, which are connected to Gene expression and Virus.
Pamela L. Zeitlin focuses on Cystic fibrosis, Internal medicine, Cystic fibrosis transmembrane conductance regulator, Endocrinology and Molecular biology. Her Cystic fibrosis research is multidisciplinary, incorporating elements of Mutation, Chloride channel, Immunology and Pathology. Her research integrates issues of Gastroenterology, Placebo and Surgery in her study of Internal medicine.
Her work deals with themes such as Phenylbutyrate, Genetic enhancement, Mutant and Cell biology, which intersect with Cystic fibrosis transmembrane conductance regulator. Her Endocrinology research integrates issues from Epithelium, Western blot and In vivo. Her Molecular biology study integrates concerns from other disciplines, such as Cell culture, Immunocytochemistry, Adeno-associated virus, Gene expression and Antibody.
Her primary areas of investigation include Cystic fibrosis, Internal medicine, Cell biology, Cystic fibrosis transmembrane conductance regulator and Immunology. The concepts of her Cystic fibrosis study are interwoven with issues in Molecular biology, Lung, Mucociliary clearance and Pathology. Her Internal medicine research incorporates themes from Gastroenterology, Chloride channel, Endocrinology and Placebo.
Her biological study spans a wide range of topics, including Ubiquitin, Respiratory epithelium and Mutation. Her Cystic fibrosis transmembrane conductance regulator research incorporates elements of Frameshift mutation, Missense mutation, Bronchiectasis and Exocrine pancreatic insufficiency. Her study in Immunology is interdisciplinary in nature, drawing from both Bronchoalveolar lavage and Microbiology.
Her main research concerns Cystic fibrosis, Internal medicine, Cystic fibrosis transmembrane conductance regulator, Lung and Chloride channel. She interconnects Endocrinology, Respiratory epithelium, Intensive care medicine, Mucociliary clearance and Nasal administration in the investigation of issues within Cystic fibrosis. Her Nasal administration research includes themes of Molecular biology, Gene expression and Genetic enhancement.
The Internal medicine study combines topics in areas such as Placebo, Tobramycin and Ataluren. Her Cystic fibrosis transmembrane conductance regulator study combines topics from a wide range of disciplines, such as Drug metabolism and Mechanism of action. Her Lung research is multidisciplinary, relying on both Immunology and Microbiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.
Terence R. Flotte;Sandra A. Afione;Carol Conrad;Sharon A. McGrath.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Defective regulation of outwardly rectifying Cl− channels by protein kinase A corrected by insertion of CFTR
Marie Egan;Terence Flotte;Terence Flotte;Sandra Afione;Rikki Solow.
Immunocytochemical localization of the cystic fibrosis gene product CFTR.
Isabelle Crawford;Peter C. Maloney;Pamela L. Zeitlin;William B. Guggino.
Proceedings of the National Academy of Sciences of the United States of America (1991)
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
Ronald C. Rubenstein;Pamela L. Zeitlin.
American Journal of Respiratory and Critical Care Medicine (1998)
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.
Benjamin C. Tang;Michelle Dawson;Michelle Dawson;Samuel K. Lai;Ying Ying Wang.
Proceedings of the National Academy of Sciences of the United States of America (2009)
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter
Terence R. Flotte;Sandra A. Afione;Rikki Solow;Mitchell L. Drumm.
Journal of Biological Chemistry (1993)
In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
Ronald C. Rubenstein;Marie E. Egan;Pamela L. Zeitlin.
Journal of Clinical Investigation (1997)
A Cystic Fibrosis Bronchial Epithelial Cell Line: Immortalization by Adeno-12-SV40 Infection
P. L. Zeitlin;L. Lu;J. Rhim;G. Cutting.
American Journal of Respiratory Cell and Molecular Biology (1991)
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Ronald L. Gibson;Julia Emerson;Sharon McNamara;Jane L. Burns.
American Journal of Respiratory and Critical Care Medicine (2003)
Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR
Ronald C. Rubenstein;Pamela L. Zeitlin.
American Journal of Physiology-cell Physiology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: